-
Product Insights
NewDiabetic Gastroparesis – Drugs In Development, 2024
Empower your strategies with our Diabetic Gastroparesis – Drugs In Development, 2024 report and make more profitable business decisions. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn,...
-
Product Insights
NewBiliary Tumor – Drugs In Development, 2024
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms...
-
Product Insights
NewGastrointestinal Tumor – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal (GI) tumors refer to abnormal growths or neoplasms that develop in various parts of the digestive system, which includes the esophagus, stomach, intestines (small and large), liver, gallbladder, and pancreas. These tumors can be benign (non-cancerous) or malignant (cancerous). The Gastrointestinal Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roducitabine in Metastatic Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Roducitabine in Metastatic Pancreatic Cancer Drug Details: Roducitabine is under development for the treatment of...
-
Product Insights
NewNet Present Value Model: Satsuma Pharmaceuticals Inc’s Dihydroergotamine Mesylate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YH-12852 in Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YH-12852 in Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YH-12852 in Gastroparesis Drug Details: YH-12852 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YH-12852 in Diabetic Gastroparesis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YH-12852 in Diabetic Gastroparesis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.YH-12852 in Diabetic Gastroparesis Drug Details:YH-12852 is under development for the treatment of...